Publications 2025

Abrantes R, Forcados C, Warren DJ, Santos-Ferreira L, Fleten KG, Senra E, Costa AF, Krpina K, Henrique R, Liberg AM, Rawat P, Gelebart P, McCormack E, Bjørge L, Davidson B, Greiff V, Costea DE, Pinto F, Flatmark K, Gomes C, Inderberg EM, Reis CA, Wälchli S (2025)
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors
6 (9), 102350
DOI 10.1016/j.xcrm.2025.102350, PubMed 40925376

Inderberg EM, Singh N, Miller R, Arbe-Barnes S, Eriksen HK, Lversen B, Juul HV, Eriksen JA, Handeland KR (2025)
Generation of frameshift-mutated TGFβR2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF in a phase 1 study
74 (4), 115
DOI 10.1007/s00262-025-03969-6, PubMed 39998682

Marhelava K, Fidyt K, Pepek M, Krawczyk M, Forcados C, Malinowska A, Swiderska B, Fernandez-Fuentes N, Czerwik N, Baranowska I, Krzywdzinska A, Sedek L, Slota L, Perkowski B, Villatoro A, Leray T, Lech-Maranda E, Menendez P, Inderberg EM, Wälchli S, Winiarska M, Firczuk M (2025)
LILRB1-directed CAR-T cells for the treatment of hematological malignancies
39 (6), 1395-1411
DOI 10.1038/s41375-025-02580-z, PubMed 40186066

Skourti E, Seip K, Mensali N, Jabeen S, Juell S, Øynebråten I, Pettersen S, Engebraaten O, Corthay A, Inderberg EM, Dolznig H, Mælandsmo GM, Egeland EV, Prasmickaite L (2025)
Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer
27 (1), 131
DOI 10.1186/s13058-025-02082-x, PubMed 40660361

Publications 2024

Bobrowicz M, Kusowska A, Krawczyk M, Zhylko A, Forcados C, Slusarczyk A, Barankiewicz J, Domagala J, Kubacz M, Šmída M, Dostalova L, Marhelava K, Fidyt K, Pepek M, Baranowska I, Szumera-Cieckiewicz A, Inderberg EM, Wälchli S, Granica M, Graczyk-Jarzynka A, Majchrzak M, Poreba M, Gehlert CL, Peipp M, Firczuk M et al. (2024)
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies
13 (1), 2362454
DOI 10.1080/2162402X.2024.2362454, PubMed 38846084

Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, Wälchli S (2024)
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812

Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S (2024)
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia
5 (6), 101572
DOI 10.1016/j.xcrm.2024.101572, PubMed 38754420

Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, Inderberg EM (2024)
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer
32 (6), 2021-2029
DOI 10.1016/j.ymthe.2024.04.009, PubMed 38582964

Rosselle L, Leray T, Joaquina S, Caulier B, McCormack E, Gelebart P, Wälchli S, Inderberg EM (2024)
Protocol for production of tonic CAR T cells with dasatinib
6 (1), 103529
DOI 10.1016/j.xpro.2024.103529, PubMed 39739533

Safont MM, Leitch C, Popa M, Gjerstad ME, Caulier B, Inderberg EM, Wälchli S, Gelebart P, McCormack E (2024)
Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy
5 (4), 103522
DOI 10.1016/j.xpro.2024.103522, PubMed 39673705

Publications 2023

Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, Wälchli S (2023)
Efficient chimeric antigen receptor targeting of a central epitope of CD22
299 (7), 104883
DOI 10.1016/j.jbc.2023.104883, PubMed 37269947

Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G (2023)
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy
37 (9), 1842-1849
DOI 10.1038/s41375-023-01980-3, PubMed 37507426

Joaquina S, Forcados C, Caulier B, Inderberg EM, Wälchli S (2023)
Determination of CAR T cell metabolism in an optimized protocol
11, 1207576
DOI 10.3389/fbioe.2023.1207576, PubMed 37409169

Klee CH, Villatoro A, Casey NP, Inderberg EM, Wälchli S (2023)
In vitro re-challenge of CAR T cells
183, 335-353
DOI 10.1016/bs.mcb.2023.06.003, PubMed 38548418

Lilleby W, Seierstad T, Inderberg EM, Hole KH (2023)
Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring
152 (10), 2166-2173
DOI 10.1002/ijc.34448, PubMed 36715014

Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P et al. (2023)
ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
14 (1), 3375
DOI 10.1038/s41467-023-39097-x, PubMed 37291203

Publications 2022

Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G (2022)
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
20 (1), 419
DOI 10.1186/s12967-022-03624-z, PubMed 36089578

Ellingsen EB, Aamdal E, Guren T, Lilleby W, Brunsvig PF, Mangsbo SM, Aamdal S, Hovig E, Mensali N, Gaudernack G, Inderberg EM (2022)
Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials
10 (5)
DOI 10.1136/jitc-2021-004345, PubMed 35613827

Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
12
DOI 10.1093/gigascience/giad032, PubMed 37161965

Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, Inderberg EM (2022)
A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT)
12, 1031232
DOI 10.3389/fonc.2022.1031232, PubMed 36439452

Mensali N, Inderberg EM (2022)
Emerging Biomarkers for Immunotherapy in Glioblastoma
14 (8)
DOI 10.3390/cancers14081940, PubMed 35454848

Publications 2021

Bousquet PA, Meltzer S, Fuglestad AJ, Lüders T, Esbensen Y, Juul HV, Johansen C, Lyckander LG, Bjørnetrø T, Inderberg EM, Kersten C, Redalen KR, Ree AH (2021)
The mitochondrial DNA constitution shaping T-cell immunity in patients with rectal cancer at high risk of metastatic progression
24 (6), 1157-1167
DOI 10.1007/s12094-021-02756-w, PubMed 34961902

Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2021)
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
10 (1), 1936757
DOI 10.1080/2162402X.2021.1936757, PubMed 34235003

Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663

Fåne A, Myhre MR, Inderberg EM, Wälchli S (2021)
In vivo experimental mouse model to test CD19CAR T cells generated with different methods
167, 149-161
DOI 10.1016/bs.mcb.2021.11.001, PubMed 35152992

Guldvik IJ, Ekseth L, Kishan AU, Stensvold A, Inderberg EM, Lilleby W (2021)
Circulating Tumor Cell Persistence Associates with Long-Term Clinical Outcome to a Therapeutic Cancer Vaccine in Prostate Cancer
11 (7)
DOI 10.3390/jpm11070605, PubMed 34206815

Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, Wälchli S (2021)
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms
35 (9), e21750
DOI 10.1096/fj.202100025R, PubMed 34424568

Tryggestad AMA, Axcrona K, Axcrona U, Bigalke I, Brennhovd B, Inderberg EM, Hønnåshagen TK, Skoge LJ, Solum G, Saebøe-Larssen S, Josefsen D, Olaussen RW, Aamdal S, Skotheim RI, Myklebust TÅ, Schendel DJ, Lilleby W, Dueland S, Kvalheim G (2021)
Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
82 (2), 245-253
DOI 10.1002/pros.24267, PubMed 34762317

Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brunsvig PF, Aamdal S, Heintz KM, Vodák D, Nakken S, Hovig E, Nyakas M, Guren TK, Gaudernack G (2021)
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial
12, 663865
DOI 10.3389/fimmu.2021.663865, PubMed 34046035

Publications 2020

Benard E, Casey NP, Inderberg EM, Wälchli S (2020)
SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy
92 (4), e12917
DOI 10.1111/sji.12917, PubMed 32557659

Brunsvig PF, Guren TK, Nyakas M, Steinfeldt-Reisse CH, Rasch W, Kyte JA, Juul HV, Aamdal S, Gaudernack G, Inderberg EM (2020)
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397

Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
29 (3), 1199-1213
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301

Dillard P, Lie M, Baken E, Lobert VH, Benard E, Köksal H, Inderberg EM, Wälchli S (2020)
Colorectal cysts as a validating tool for CAR therapy
20 (1), 30
DOI 10.1186/s12896-020-00623-0, PubMed 32487146

Inderberg EM, Wälchli S (2020)
Long-term surviving cancer patients as a source of therapeutic TCR
69 (5), 859-865
DOI 10.1007/s00262-019-02468-9, PubMed 31915853

Inderberg EM, Wälchli S (2020)
Sympathetic improvement of cancer vaccine efficacy
16 (8), 1888-1890
DOI 10.1080/21645515.2019.1703456, PubMed 31977269

Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2020)
Combinatorial CAR design improves target restriction
296, 100116
DOI 10.1074/jbc.RA120.016234, PubMed 33234592

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2020)
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
69 (1), 159-161
DOI 10.1007/s00262-019-02409-6, PubMed 31776597

Weum Abrahamsen I, Grønvold BC, Inderberg EM, Mensali N, Mattsson J, Gedde-Dahl T (2020)
Posttransplantation Lymphoproliferative Disease Treated by Retransplantation
2020, 9403123
DOI 10.1155/2020/9403123, PubMed 32158568

Winge-Main AK, Wälchli S, Inderberg EM (2020)
T cell receptor therapy against melanoma-Immunotherapy for the future?
92 (4), e12927
DOI 10.1111/sji.12927, PubMed 32640053

Publications 2019

Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
59 (4), 404-409
DOI 10.1080/0284186X.2019.1704864, PubMed 31876430

Köksal H, Baken E, Warren DJ, Løset GÅ, Inderberg EM, Wälchli S (2019)
Chimeric antigen receptor preparation from hybridoma to T-cell expression
2 (2), 56-63
DOI 10.1093/abt/tbz007, PubMed 33928223

Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, Wälchli S (2019)
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
3 (8), 1230-1243
DOI 10.1182/bloodadvances.2018029678, PubMed 30979721

Köksal H, Müller E, Inderberg EM, Bruland Ø, Wälchli S (2019)
Treating osteosarcoma with CAR T cells
89 (3), e12741
DOI 10.1111/sji.12741, PubMed 30549299

Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Wälchli S (2019)
NK cells specifically TCR-dressed to kill cancer cells
40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853

Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, Wälchli S (2019)
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591

Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, Inderberg EM (2019)
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732

Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, Berg K (2019)
Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy
5, 13
DOI 10.1038/s41523-019-0108-8, PubMed 30993194

Publications 2018

Dillard P, Köksal H, Inderberg EM, Wälchli S (2018)
A Spheroid Killing Assay by CAR T Cells
(142)
DOI 10.3791/58785, PubMed 30596389

Våtsveen TK, Myhre MR, Steen CB, Wälchli S, Lingjærde OC, Bai B, Dillard P, Theodossiou TA, Holien T, Sundan A, Inderberg EM, Smeland EB, Myklebust JH, Oksvold MP (2018)
Artesunate shows potent anti-tumor activity in B-cell lymphoma
11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389

Publications 2017

Inderberg EM, Mensali N, Oksvold MP, Fallang LE, Fåne A, Skorstad G, Stenvik GE, Progida C, Bakke O, Kvalheim G, Myklebust JH, Wälchli S (2017)
Human c-SRC kinase (CSK) overexpression makes T cells dummy
67 (4), 525-536
DOI 10.1007/s00262-017-2105-9, PubMed 29248956

Inderberg EM, Wälchli S, Myhre MR, Trachsel S, Almåsbak H, Kvalheim G, Gaudernack G (2017)
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Lilleby W, Gaudernack G, Brunsvig PF, Vlatkovic L, Schulz M, Mills K, Hole KH, Inderberg EM (2017)
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
66 (7), 891-901
DOI 10.1007/s00262-017-1994-y, PubMed 28391357

Walseng E, Köksal H, Sektioglu IM, Fåne A, Skorstad G, Kvalheim G, Gaudernack G, Inderberg EM, Wälchli S (2017)
A TCR-based Chimeric Antigen Receptor
7 (1), 10713
DOI 10.1038/s41598-017-11126-y, PubMed 28878363

Publications 2016

Kyte JA, Gaudernack G, Faane A, Lislerud K, Inderberg EM, Brunsvig P, Aamdal S, Kvalheim G, Wälchli S, Pule M (2016)
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy
5 (12), e1249090
DOI 10.1080/2162402X.2016.1249090, PubMed 28123886

Kyte JA, Aamdal S, Dueland S, Sæbøe-Larsen S, Inderberg EM, Madsbu UE, Skovlund E, Gaudernack G, Kvalheim G (2016)
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells
5 (11), e1232237
DOI 10.1080/2162402X.2016.1232237, PubMed 27999747

Publications 2015

Almåsbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, Kyte JA (2015)
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098

Publications 2013

Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tønnesen P, Suso EM, Sæbøe-Larssen S, Sandberg C, Brinchmann JE, Helseth E, Rasmussen AM, Lote K, Aamdal S, Gaudernack G, Kvalheim G, Langmoen IA (2013)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721

Publications 2012

Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
1 (5), 670-686
DOI 10.4161/onci.20426, PubMed 22934259

Publications 2011

Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
60 (6), 809-18
DOI 10.1007/s00262-011-0991-9, PubMed 21365467